Sugi Predict

Sugi Predict / Targets / PRKX

PRKX

cAMP-dependent protein kinase catalytic subunit PRKX · P51817 · PRKX on Sugi Atlas →

48,386 patent compounds predicted against PRKX, 32,939 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL363119 SCHEMBL363119 0.44 4/20
SCHEMBL363116 SCHEMBL363116 0.39 4/20
SCHEMBL369534 SCHEMBL369534 0.39 4/20
SCHEMBL369535 SCHEMBL369535 0.39 4/20
A-443654 A-443654 (SCHEMBL570604) 1.00 3/20
Rosoxacin Rosoxacin (SCHEMBL135645) 0.48 3/20
SCHEMBL413480 SCHEMBL413480 0.46 3/20
SCHEMBL361993 SCHEMBL361993 0.38 3/20
SCHEMBL363842 SCHEMBL363842 0.37 3/20
SCHEMBL363521 SCHEMBL363521 0.36 3/20
SCHEMBL363855 SCHEMBL363855 0.36 3/20
SCHEMBL364346 SCHEMBL364346 0.36 3/20
SCHEMBL365733 SCHEMBL365733 0.36 3/20
Fasudil Fasudil (SCHEMBL4674) 1.00 2/20
SCHEMBL124161 SCHEMBL124161 1.00 2/20
Y-27632 Y-27632 (SCHEMBL190356) 1.00 2/20
SCHEMBL226317 SCHEMBL226317 1.00 2/20
Y-27632 Y-27632 (SCHEMBL342816) 1.00 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL507871) 0.98 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL507872) 0.98 2/20

Clinical trials — most relevant to PRKX by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK PHASE4UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds PHASE2/PHASE3COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) PHASE2COMPLETED
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism. PHASE1COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure nanCOMPLETED
IL-17 Role in Variants of Psoriasis nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy. nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Study of Constitutional Platelet Disease nanUNKNOWN
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKX binder may also engage these)

ProteinNameSimilarity
Q922R0 — 0.994 Q922R0 →
Q8R4U9 — 0.990 Q8R4U9 →
O43930 — 0.987 O43930 →
Q9QZS5 — 0.983 Q9QZS5 →
SGK2 Serine/threonine-protein kinase Sgk2 0.982 landscape →
P49673 — 0.978 P49673 →
PRKACG cAMP-dependent protein kinase catalytic subunit gamma 0.978 landscape →
P68181 — 0.977 P68181 →
P54644 — 0.977 P54644 →
Q16974 — 0.976 Q16974 →
Q9WVC6 — 0.976 Q9WVC6 →
Q6U1I9 — 0.975 Q6U1I9 →
P68182 — 0.974 P68182 →
PRKCA Protein kinase C alpha type 0.974 landscape →
P21137 — 0.974 P21137 →
A8KBH6 — 0.973 A8KBH6 →
P06245 — 0.973 P06245 →
PRKCB Protein kinase C beta type 0.973 landscape →
P05383 — 0.973 P05383 →
Q9ERE3 — 0.972 Q9ERE3 →
Q9XT18 — 0.972 Q9XT18 →
P63319 — 0.972 P63319 →
P63318 — 0.972 P63318 →
P05128 — 0.971 P05128 →
Q4R4U2 — 0.971 Q4R4U2 →
P04409 — 0.971 P04409 →
SGK1 Serine/threonine-protein kinase Sgk1 0.971 landscape →
P06244 — 0.971 P06244 →
P12370 — 0.971 P12370 →
A8XJQ6 — 0.971 A8XJQ6 →